Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1868-1875

  Blanco, Delia ^a   Perez Herran, Esther ^a   Cacho, Mónica ^a   Ballell, Lluís ^a   Castro, Julia ^a   Del Río, Rubén González ^a   Lavandera, José Luis ^a,d   Remuiñán, Modesto J ^a   Richards, Cindy ^b   Rullas, Joaquin ^a   Vázquez Muñiz, María Jesús ^c   Woldu, Ermias ^b   Zapatero González, María Cleofé ^c   Angulo Barturen, Iñigo ^a   Mendoza, Alfonso ^a   Barros, David ^a  

^a Diseases of the developing world   (Spain)

^b GLAXOSMITHKLINE   (United States)

^c GSK   (Spain)

^d UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GYRASE INHIBITOR; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; TUBERCULOSTATIC AGENT; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRINSIC CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM BOVIS; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; FEMALE; FLUOROQUINOLONES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TOPOISOMERASE I INHIBITORS; TUBERCULOSIS;

EID: 84928901525     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03913-14     Document Type: Article

References (40)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.
3. World Health Organization. 2006. The stop TB strategy. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/strategy/en/.
4. World Health Organization. 2009. Treatment of tuberculosis: guidelines for national programs, 4th ed. WHO/HTM/TB/2009.420. World Health Organization, Geneva, Switzerland.
5. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. World Health Organization, Geneva, Switzerland.
6. Migliori GB, Centis R, D'Ambrosio L, Spanevello A, Borroni E, Cirillo DM, Sotgiu G. 2012. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis 54:1379-1380. http://dx.doi.org/10.1093/cid/cis128.
7. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420-425. http://dx.doi.org/10.1378/chest.08-2427.
8. Bax B, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewi CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-943. http://dx.doi.org/10.1038/nature09197.
9. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD. 2010. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17:1152-1153. http://dx.doi.org/10.1038/nsmb.1892.
10. Miles TJ, Axten JM, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Gallagher T, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Miller WH, Minthorn EA, Rittenhouse S, Seefeld M, Pearson N. 2011. Novel aminopiperidines as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 21:7489-7495. http://dx.doi.org/10.1016/j.bmcl.2011.09.117.
11. Miles TJ, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Rittenhouse S, Xiang H, Pearson N. 2011. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett 21:7483-7488. http://dx.doi.org/10.1016/j.bmcl.2011.09.114.
12. Alemparte-Gallardo C, Ballell-Pages L, Barros-Aguirre D, Cacho-Izquierdo M, Castro-Pichel J, Fiandor-Roman JM, Hennessy AJ, Pearson ND, Remuinan-Blanco MJ. July 2009. Naphthyridin-2(1H)-one compounds useful as antibacterials. International patent application WO 2009/090222 A1 20090723.
13. Alemparte-Gallardo C, Barros-Aguirre D, Cacho-Izquierdo M, Fiandor-Roman JM, Remuinan Blanco MJ. November 2009. Preparation of tricyclic nitrogen containing compounds as antibacterials. International patent application WO 2009/141399 A1 20091126.
14. Alemparte-Gallardo C, Barros-Aguirre D, Cacho-Izquierdo M, Fiandor-Roman JM, Lavandera Diaz JL, Remuinan-Blanco MJ. July 2010. Naphthyridin-2(1H)-one compounds as antibacterials and their preparation and use for the treatment of bacterial infections. International patent application WO 2010/081874 A1 20100722.
15. Barros D. December 2009. Recent advances in TB drug development, novel Mtb DNA gyrase inhibitors: MGIs. In Proceedings of the 40th Union World Conference on Lung Health, Cancun, Mexico.
16. Hameed P, Patil V, Solapure S, Sharma U, Madhavapeddi M, Raichurkar A, Chinnapattu M, Manjrekar P, Shanbhag G, Puttur J, Shinde V, Menasinakai S, Rudrapatana S, Achar V, Awasthy D, Nandishaiah R, Humnabadkar V, Ghosh A, Narayan C, Kaur P, Sharma S, Wirngren J, Hoffner S, Panduga V, Kumar CNN, Reddy J, Ganguly S, Bharath Bheemarao SU, Mukherjee K, Arora U, Gaonkar S, Coulson M, Waterson D, Sambandamurthy VK, Desousa SM. 2014. Novel N-linked aminopiperidine based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. J Med Chem 57:4889-4905. http://dx.doi.org/10.1021/jm500432n.
17. Ballell L, Barros D, Brooks G, Castro J, Dabbs S, Daines RA, Davies DT, Fiandor Roman JM, Giordano I, Hennessy AJ, Hoffman JB, Jones GE, Miles TJ, Pearson ND, Pendrak I, Remuinan Blanco MJ, Rossi JS, Zhang L. January 2008. Derivatives and analogues of N-ethylquinolones and N-ethylazaquinolones as antibacterial agents and their reparation. International patent application WO 2008/009700 A1 20080124.
18. Sambrook J, Russell DW. 2001. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
19. Parish T, Stoker NG. 2001. Mycobacterial protocols. Springer Science Business Media, New York, NY.
20. Martin A, Camacho M, Portaels F, Palomino JC. 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 47:3616-3619. http://dx.doi.org/10.1128/AAC.47.11 .3616-3619.2003.
21. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR, Telenti A. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38:773-780. http://dx.doi.org/10.1128/AAC.38.4.773.
22. Parish T, Stoker NG. 2000. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 146(Pt 8):1969-1975.
23. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosisDNAgyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48:1281-1288. http://dx.doi.org/10.1128/AAC.48.4.1281-1288.2004.
24. Ginsburg A, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 3:432-442. http://dx.doi.org/10.1016/S1473-3099(03)00671-6.
25. Rullas J, García JI, Beltrán M, Cardona P-J, Cáceres N, García-Bustos JF, Angulo-Barturen I. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 54:2262-2264. http://dx.doi.org/10.1128/AAC.01423-09.
26. Chemical Computing Group. 2010. Molecular operating environment molecular modeling program (MOE), version 2010.04. Chemical Computing Group, Montreal, QC, Canada.
27. Cambridge Crystallographic Data Centre. GOLD, version 4.01. CCDC, Cambridge, United Kingdom.
28. Jamieson C, Moir EM, Rankovic Z, Wishert GJ. 2006. Medicinal chemistry of hERG optimizations: highlights and hang-ups. J Med Chem 49: 5029-5046. http://dx.doi.org/10.1021/jm060379l.
29. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51:576-582. http://dx.doi.org/10.1128/AAC.00414-06.
30. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67:819-831. http://dx.doi.org/10.1093/jac/dkr566.
31. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, Da Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 53:4498-4500. http://dx.doi.org/10.1128/AAC.00287-09.
32. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Navskaya O, Rastogi N. 2008. Molecular characterization of ofloxacinresistant Mycobacterium tuberculosis strains Russia. Antimicrob Agents Chemother 52:2937-2939. http://dx.doi.org/10.1128/AAC.00036-08.
33. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher M. 2006. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50:104-112. http://dx.doi.org/10.1128/AAC.50.1.104-112.2006.
34. Yin X, Yu Z. 2010. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect 61:150-154. http://dx.doi.org/10.1016/j.jinf.2010.05.001.
35. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, Li C. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 31:115-121. http://dx.doi.org/10.1016/j.ijantimicag.2007.10.014.
36. Singh PK, Chan P, Hibbs M, Segura D, Vazquez MJ, Thomas DA, Theobald AJ, Gallagher KT, Hassan NJ. 2011. High-yield production and characterization of biologically active GST tagged human topoisomerase IIa protein in insect cells for the development of a high-throughput assay. Protein Expr Purif 76:165-172. http://dx.doi.org/10.1016/j.pep .2010.08.001.
37. Young RJ, Green DVS, Luscombe CN, Hill AP. 2011. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today 16:822-830. http://dx.doi.org/10.1016/j.drudis.2011.06.001.
38. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. 2005. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26:590-597. http://dx.doi.org/10.1093/eurheartj/ehi092.
39. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45. http://dx.doi.org/10.1016/S0008-6363(02)00846-5.
40. Pollard CE, Valentin JP, Hammond TG. 2008. Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154:1538-1543. http://dx.doi.org/10.1038/bjp.2008.203.